20n Bio (pr. "twenty-n bio") is a VC-backed startup dedicated to discovering cyclic peptides for therapeutic use. Based in the Greater Philadelphia region, 20n Bio's mission is to address unmet medical needs by leveraging high-throughput screening and chemical optimization to develop peptide drugs across various therapeutic areas.

Our Focus

Peptides offer the best of both small molecules and antibodies, demonstrating significant therapeutic potential across a wide range of modalities, including oral peptides, radioligand therapy, peptide-drug conjugates, etc. Their versatility enables them to target diverse biological pathways, making them suitable for treating conditions from metabolic disorders to complex cancers. While most FDA-approved peptide drugs are natural derivatives, demand in de novo peptide discovery for targets with no known natural ligands is surging. 

20n Bio has developed a proprietary peptide discovery platform capable of screening libraries containing trillions of peptides at once, offering unparalleled potential to identify the most potent candidates. The platform efficiently navigates the immense peptide sequence space to identify peptides with optimal binding and therapeutic properties quickly. This ability to discover high-affinity peptides de novo opens new avenues for developing innovative treatments to address unmet medical needs.

In addition to internal pipeline development, 20n Bio has successfully built a series of partnerships with pharmaceutical and biotechnology companies by licensing early hits and providing customized solutions to help bring novel peptide therapeutics to market efficiently. As the demand for targeted and effective therapies continues to grow, 20n Bio is at the forefront of peptide innovation, driving advancements that are shaping the future of modern medicine.

Leadership Team

We are a group of peptide believers. 

We encourage enthusiastic scientists to join us to fulfill our mission.

Company News

Jan 31, 2024: 20n Bio Appoints Linghang Zhuang, Ph.D., as President, to lead the discovery of cyclic peptide drugs.

Dec 17, 2021: 20n Bio 20n Bio Raises $3.3 Million in Series Seed Funding.